Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guangzhou Women And Children'S Medical Center maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions currently in progress. These actions are spread across 2 distinct art units. Prosecution is being handled by 2 distinct examiners.
The busiest examiner identified is VYAS, KEYUR ANILKUMAR, who is responsible for 1 busiest examiner pending office action. This 1 action is part of the 2 pending office actions for the portfolio. The remaining action is handled by another of the 2 distinct examiners. This distribution requires the applicant to manage separate tracks of communication and technical negotiation.
With 2 distinct art units involved, the legal team must tailor its responses to the specific requirements of each unit. The presence of 2 distinct examiners means that the prosecution strategy must account for different perspectives. While VYAS, KEYUR ANILKUMAR handles 1 pending office action, the overall portfolio management must address the different examiner styles present across the active cases for Guangzhou Women And Children'S Medical Center.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022505 | USE OF MCM8-CGAS-STING-IFN-I SIGNAL PATHWAY AS DISEASE TARGET | VYAS, KEYUR ANILKUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022505 | USE OF MCM8-CGAS-STING-IFN-I SIGNAL PATHWAY AS DISEASE TARGET | VYAS, KEYUR ANILKUMAR | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022505 | USE OF MCM8-CGAS-STING-IFN-I SIGNAL PATHWAY AS DISEASE TARGET | VYAS, KEYUR ANILKUMAR | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial